Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
Status:
RECRUITING
Trial end date:
2026-03-20
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, single-arm clinical study on the treatment of newly diagnosed diffuse large B-cell lymphoma with high-risk of CNS relapse defined by CNS-IPI using Orelabrutinib in combination with R-CDOP regimen.
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Affiliated Hospital of Jiaxing University Huizhou Municipal Central Hospital Ningbo Medical Center Lihuili Hospital Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University The Second Affiliated Hospital of Jiaxing University